Literature DB >> 25437913

Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation.

Neroshan Thevakumaran1, Hugo Lavoie2, David A Critton3, Andrew Tebben3, Anne Marinier2, Frank Sicheri4, Marc Therrien5.   

Abstract

Reported RAF kinase domain structures adopt a side-to-side dimer configuration reflective of an 'on' state that underpins an allosteric mechanism of regulation. Atomic details of the monomer 'off' state have been elusive. Reinspection of the BRAF kinase domain structures revealed that sulfonamide inhibitors induce features of an off state, primarily a laterally displaced helix αC stabilized by the activation segment helix 1 (AS-H1). These features correlated with the ability of sulfonamides to disrupt human BRAF homodimers in cells, in vitro and in crystals yielding a structure of BRAF in a monomer state. The crystal structure revealed exaggerated, nonproductive positions of helix αC and AS-H1, the latter of which is the target of potent BRAF oncogenic mutations. Together, this work provides formal proof of an allosteric link between the RAF dimer interface, the activation segment and the catalytic infrastructure.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25437913     DOI: 10.1038/nsmb.2924

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  34 in total

Review 1.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

2.  Oligomerization activates c-Raf-1 through a Ras-dependent mechanism.

Authors:  Z Luo; G Tzivion; P J Belshaw; D Vavvas; M Marshall; J Avruch
Journal:  Nature       Date:  1996-09-12       Impact factor: 49.962

3.  Proteomic analysis of scaffold proteins in the ERK cascade.

Authors:  Melissa M McKay; Deborah K Morrison
Journal:  Methods Mol Biol       Date:  2010

4.  Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.

Authors:  B H Zhang; K L Guan
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

5.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.

Authors:  Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2010-10-15       Impact factor: 16.971

8.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

9.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

10.  Architecture and membrane interactions of the EGF receptor.

Authors:  Anton Arkhipov; Yibing Shan; Rahul Das; Nicholas F Endres; Michael P Eastwood; David E Wemmer; John Kuriyan; David E Shaw
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

View more
  61 in total

1.  Knock-in(g) RAF for a loop.

Authors:  Andrea Varga; Manuela Baccarini
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

2.  BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Authors:  Michael J Vido; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

3.  Molecular Mechanism of Protein Kinase Recognition and Sorting by the Hsp90 Kinome-Specific Cochaperone Cdc37.

Authors:  Dimitra Keramisanou; Adam Aboalroub; Ziming Zhang; Wenjun Liu; Devon Marshall; Andrea Diviney; Randy W Larsen; Ralf Landgraf; Ioannis Gelis
Journal:  Mol Cell       Date:  2016-04-21       Impact factor: 17.970

Review 4.  Regulation of RAF protein kinases in ERK signalling.

Authors:  Hugo Lavoie; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05       Impact factor: 94.444

5.  Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK.

Authors:  Peter Kubiniok; Hugo Lavoie; Marc Therrien; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2017-02-10       Impact factor: 5.911

Review 6.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

7.  Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation.

Authors:  Michael Grasso; Michelle A Estrada; Christian Ventocilla; Minu Samanta; Jasna Maksimoska; Jessie Villanueva; Jeffrey D Winkler; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2016-09-06       Impact factor: 5.100

8.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Authors:  Zoi Karoulia; Yang Wu; Tamer A Ahmed; Qisheng Xin; Julien Bollard; Clemens Krepler; Xuewei Wu; Chao Zhang; Gideon Bollag; Meenhard Herlyn; James A Fagin; Amaia Lujambio; Evripidis Gavathiotis; Poulikos I Poulikakos
Journal:  Cancer Cell       Date:  2016-08-11       Impact factor: 31.743

9.  Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.

Authors:  Martin Köhler; Michael Röring; Björn Schorch; Katharina Heilmann; Natalie Stickel; Gina J Fiala; Lisa C Schmitt; Sandra Braun; Sophia Ehrenfeld; Franziska M Uhl; Thorsten Kaltenbacher; Florian Weinberg; Sebastian Herzog; Robert Zeiser; Wolfgang W Schamel; Hassan Jumaa; Tilman Brummer
Journal:  EMBO J       Date:  2015-12-10       Impact factor: 11.598

10.  Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.

Authors:  Yuanyuan Li; David M Umbach; Leping Li
Journal:  Melanoma Res       Date:  2017-12       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.